#mesoblast

[pknoepfl]

Mesoblast stock hit on gloomy data on stem cells for COVID-19

Mesoblast stock hit on gloomy data on stem cells for COVID-19

I’ve been closely following the arena of stem cells for COVID-19 since the pandemic broke including the efforts of Mesoblast. Mesoblast unlikely to meet primary endpoints in Phase III COVID trial Mesoblast CEO Silvio Itescu. Now, the firm got bad news as its DSMB reported that they are unlikely to meet the primary endpoint for their Phase III trial of their stem cell product for COVID-19 based on…

View On WordPress

[pknoepfl]

Mesoblast MSCs Quell Peds GvHD, On Road to FDA Approval

Mesoblast MSCs Quell Peds GvHD, On Road to FDA Approval

Graft-versus-host disease (GVHD) is counterintuitive

In the weeks and months following a transplant, a major concern is the recipient’s immune system rejecting the “foreign” biological material. But in GVHD, the opposite happens: transplanted tissue unleashes a horde of T cells that spark a cascade of inflammation, within 100 days. Typically, GVHD follows a bone marrow transplant (BMT).

Eighty…

View On WordPress

[pknoepfl]

Recommended reads: COVID-19 updates, FDA stem cell nod, PRC2, more

Recommended reads: COVID-19 updates, FDA stem cell nod, PRC2, more

Today’s post is the latest edition of my weekly recommended reads, which this week include Fate Therapeutics, COVID-19 updates, AAMC, and more including some great pubs such as one on 2 modes of PRC2 function.

Fig. 3d Rai et al Nature Communications 2020 “representative images of podosomes by confocal microscopy at 63× magnification. Scale bar 10 μm.”

Also check out this handy resource: Helpful…

View On WordPress

[pknoepfl]

New Mesoblast "COVID kid" stem cell study

New Mesoblast “COVID kid” stem cell study

Dr Fred Grossman, CMO Mesoblast.

The biotech Mesoblast is starting a compassionate use study of its stem cell product for kids with a severe offshoot of COVID-19.

The cellular drug in this case is remestemcel-L (more below).

While most children fare better than adults in dealing with COVID-19, the rare subset of kids with COVID-19 for this study have more severe disease than the average COVID…

View On WordPress

[au-utd-today]

[au-utd-today]

[au-utd-today]

Mesoblast completes $75 million capital raising

[worldfinancialdata-blog]

Mesoblast Limited is engaged in developing cell-based medicines.